KalVista Pharmaceuticals Company Profile (NASDAQ:KALV)

About KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals logoKalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KALV
  • CUSIP: N/A
  • Web: www.kalvista.com
Capitalization:
  • Market Cap: $126.46 million
  • Outstanding Shares: 9,713,000
Average Prices:
  • 50 Day Moving Avg: $8.00
  • 200 Day Moving Avg: $8.00
  • 52 Week Range: $5.48 - $15.80
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.52
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $625,000.00
  • Price / Sales: 202.34
  • Book Value: $2.75 per share
  • Price / Book: 4.73
Profitability:
  • EBITDA: ($16,210,000.00)
  • Net Margins: -4,191.47%
  • Return on Equity: -60.42%
  • Return on Assets: -55.11%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 7.88%
  • Quick Ratio: 7.88%
Misc:
  • Average Volume: 300,460 shs.
  • Beta: 2.54
  • Short Ratio: 11.72
 

Frequently Asked Questions for KalVista Pharmaceuticals (NASDAQ:KALV)

What is KalVista Pharmaceuticals' stock symbol?

KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its earnings results on Thursday, September, 14th. The company reported ($0.51) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.59) by $0.08. The business earned $0.10 million during the quarter. KalVista Pharmaceuticals had a negative return on equity of 60.42% and a negative net margin of 4,191.47%. View KalVista Pharmaceuticals' Earnings History.

Where is KalVista Pharmaceuticals' stock going? Where will KalVista Pharmaceuticals' stock price be in 2017?

1 brokerages have issued 12-month price targets for KalVista Pharmaceuticals' shares. Their predictions range from $27.00 to $27.00. On average, they expect KalVista Pharmaceuticals' share price to reach $27.00 in the next twelve months. View Analyst Ratings for KalVista Pharmaceuticals.

Who are some of KalVista Pharmaceuticals' key competitors?

Who are KalVista Pharmaceuticals' key executives?

KalVista Pharmaceuticals' management team includes the folowing people:

  • Richard Aldrich, Chairman of the Board
  • Thomas Andrew Crockett, Chief Executive Officer, Director
  • Benjamin L. Palleiko, Chief Financial Officer
  • Christopher Yea Ph.D., Chief Development Officer
  • Arnold L. Oronsky Ph.D., Director
  • Joshua Resnick M.D., Director
  • Rajeev Shah, Director
  • Albert Cha M.D. Ph.D., Independent Director
  • Edward W. Unkart CPA, Independent Director

How do I buy KalVista Pharmaceuticals stock?

Shares of KalVista Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KalVista Pharmaceuticals' stock price today?

One share of KalVista Pharmaceuticals stock can currently be purchased for approximately $13.02.


MarketBeat Community Rating for KalVista Pharmaceuticals (NASDAQ KALV)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  151
MarketBeat's community ratings are surveys of what our community members think about KalVista Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for KalVista Pharmaceuticals (NASDAQ:KALV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.00 (107.37% upside)
Consensus Price Target History for KalVista Pharmaceuticals (NASDAQ:KALV)
Price Target History for KalVista Pharmaceuticals (NASDAQ:KALV)
Analysts' Ratings History for KalVista Pharmaceuticals (NASDAQ:KALV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017BTIG ResearchBoost Price TargetBuy$18.00 -> $27.00N/AView Rating Details
4/18/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$9.00 -> $8.00N/AView Rating Details
2/29/2016WedbushReiterated RatingOutperform$14.00N/AView Rating Details
2/2/2016Leerink SwannDowngradeOutperform -> Market Perform$15.00 -> $1.80N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for KalVista Pharmaceuticals (NASDAQ:KALV)
Earnings by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)
Earnings History by Quarter for KalVista Pharmaceuticals (NASDAQ KALV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/14/2017Q1 2018($0.59)($0.51)$0.10 millionViewN/AView Earnings Details
7/27/2017Q4 2017($0.43)$0.11 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.21)($0.09)$0.01 millionViewN/AView Earnings Details
11/11/2015Q315($0.26)($0.19)$0.01 million$0.01 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.37)$0.01 million$0.01 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for KalVista Pharmaceuticals (NASDAQ:KALV)
Current Year EPS Consensus Estimate: $-2.49 EPS
Next Year EPS Consensus Estimate: $-2.88 EPS

Dividends

Dividend History for KalVista Pharmaceuticals (NASDAQ:KALV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for KalVista Pharmaceuticals (NASDAQ:KALV)
Insider Ownership Percentage: 49.10%
Institutional Ownership Percentage: 75.66%
Insider Trades by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)
Institutional Ownership by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)
Insider Trades by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/12/2017Holdings A/S NovoMajor ShareholderSell2,725,283$9.64$26,271,728.12View SEC Filing  
10/12/2017Rajeev M ShahDirectorBuy850,000$8.50$7,225,000.00View SEC Filing  
9/15/2017Holdings A/S NovoMajor ShareholderSell176,647$7.21$1,273,624.87View SEC Filing  
9/14/2017Holdings A/S NovoMajor ShareholderSell10,000$8.05$80,500.00View SEC Filing  
9/13/2017Holdings A/S NovoMajor ShareholderSell25,900$8.02$207,718.00View SEC Filing  
12/30/2015David RenziCEOSell10,000$3.70$37,000.00View SEC Filing  
4/14/2015Acmp Iv LlcMajor ShareholderBuy877,500$5.00$4,387,500.00View SEC Filing  
4/14/2015Albert ChaDirectorBuy1,012,500$5.00$5,062,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for KalVista Pharmaceuticals (NASDAQ:KALV)
Latest Headlines for KalVista Pharmaceuticals (NASDAQ:KALV)
Source:
Loading headlines, please wait.

Social

Chart

KalVista Pharmaceuticals (KALV) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.